This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linkov, F. Articles by Ferris, R. L. Search for Related Content PubMed PubMed Citation Articles by Linkov, F. Articles by Ferris, R. L. Related Collections Early Detection Early Detection: Biomarkers: Discovery, Methodology, Validation

Early Detection of Head and Neck Cancer: Development of a Novel Screening Tool Using Multiplexed Immunobead-Based Biomarker Profiling

¹ Department of Medicine, University of Pittsburgh Cancer Institute; ² Strategic Business Initiatives and ³ Department of Otolaryngology, University of Pittsburgh Medical Center; and Departments of ⁴ Immunology and ⁵ Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania

Requests for reprints: Robert L. Ferris, Departments of Otolaryngology and of Immunology, University of Pittsburgh Cancer Institute, Hillman Cancer Center-Research Wing, Room 2.26b, 5117 Centre Avenue, Pittsburgh, PA 15213. Phone: 412-623-7771; Fax: 412-623-7768. E-mail: ferrisrl{at}upmc.edu

Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive disease that has been linked to altered immune, inflammatory, and angiogenesis responses. A better understanding of these aberrant responses might improve early detection and prognosis of SCCHN and provide novel therapeutic targets. Previous studies examined the role of multiplexed serum biomarkers in small cohorts or SCCHN sera. We hypothesized that an expanded panel comprised of multiple cytokines, chemokines, growth factors, and other tumor markers, which individually may show some promising correlation with disease status, might provide higher diagnostic power if used in combination. Thus, we evaluated a novel multianalyte LabMAP profiling technology that allows simultaneous measurement of multiple serum biomarkers. Concentrations of 60 cytokines, growth factors, and tumor antigens were measured in the sera of 116 SCCHN patients before treatment (active disease group), 103 patients who were successfully treated (no evidence of disease group), and 117 smoker controls without evidence of cancer. The multimarker panel offering the highest diagnostic power was comprised of 25 biomarkers, including epidermal growth factor, epidermal growth factor receptor, interleukin (IL)-8, tissue plasminogen activator inhibitor-1, -fetoprotein, matrix metalloproteinase-2, matrix metalloproteinase-3, IFN-, IFN-, IFN-inducible protein-10, regulated on activation, normal T-cell expressed and secreted (RANTES), macrophage inflammatory protein-1, IL-7, IL-17, IL-1 receptor-, IL-2 receptor, granulocyte colony-stimulating factor, mesothelin, insulin-like growth factor binding protein 1, E-selectin, cytokeratin-19, vascular cell adhesion molecule, and cancer antigen-125. Statistical analysis using an ADE algorithm resulted in a sensitivity of 84.5%, specificity of 98%, and 92% of patients in the active disease group correctly classified from a cross-validation serum set. The data presented show that simultaneous testing using a multiplexed panel of serum biomarkers may present a promising new approach for the early detection of head and neck cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(1):102–7)

This article has been cited by other articles:

				A.-D. Gu, H.-Y. Mo, Y.-B. Xie, R.-J. Peng, J.-X. Bei, J. Peng, M.-Y. Li, L.-Z. Chen, Q.-S. Feng, W.-H. Jia, et al. Evaluation of a Multianalyte Profiling Assay and an Enzyme-Linked Immunosorbent Assay for Serological Examination of Epstein-Barr Virus-Specific Antibody Responses in Diagnosis of Nasopharyngeal Carcinoma Clin. Vaccine Immunol., November 1, 2008; 15(11): 1684 - 1688. [Abstract] [Full Text] [PDF]

				R. Ralhan, L. V. DeSouza, A. Matta, S. Chandra Tripathi, S. Ghanny, S. Datta Gupta, S. Bahadur, and K. W. M. Siu Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2008; 7(6): 1162 - 1173. [Abstract] [Full Text] [PDF]

				M. E. Couch, R. L. Ferris, J. A. Brennan, W. M. Koch, E. M. Jaffee, M. S. Leibowitz, G. T. Nepom, H. A. Erlich, and D. Sidransky Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7199 - 7206. [Abstract] [Full Text] [PDF]

				R. L. Ferris and J. R. Grandis NF-{kappa}B Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5663 - 5664. [Full Text] [PDF]

				H. K. Roy and J. D. Khandekar Biomarkers for the Early Detection of Cancer: An Inflammatory Concept Arch Intern Med, September 24, 2007; 167(17): 1822 - 1824. [Full Text] [PDF]